Livzon Pharmaceutical Group Inc
SZSE:000513
Livzon Pharmaceutical Group Inc
SZSE:000513
Price:
38.45 CNY
-2.44%
Updated:
May 22, 2024
P/E
Price to Earnings
Price to Earnings
17.9
Current
17.9
Median
23.5
Industry
Higher
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=17.9
Market Cap
/
35.5B
Net Income
2B
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
|
Livzon Pharmaceutical Group Inc
SZSE:000513
|
35.5B CNY | 17.9 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 347 888.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
763.3B USD | 124.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4.1T DKK | 46.3 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | -15 783.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
363.3B USD | 9.4 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
330.5B USD | 143.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
191.7B GBP | 38.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
188B CHF | 16.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
183.5B CHF | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.7B USD | -523.2 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
16
2-Years Forward
P/E
14.2
3-Years Forward
P/E
13
You don't have any saved screeners yet
